Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
Milestone Pharmaceuticals Stock
Milestone Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Joseph G. Oliveto
- Employees
- 38
- Market cap
- $96 M
- IPO
- 09/05/2019
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials…
Milestone Pharmaceuticals stock: price history
1D
-4.0%
1W
+1.2%
1M
-21.1%
6M
-61.9%
YTD
-61.7%
1Y
-61.1%
2Y
-46.6%
5Y
-86.2%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~28% weaker price swings than usual
Ask the agents about Milestone Pharmaceuticals
Analyst assessment of Milestone Pharmaceuticals
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 03/09/2026
Milestone Pharmaceuticals stock metrics
P/E
-1.11
P/B
5.86
EV/EBITDA
-0.93
RETURN ON EQUITY
-157.1%
NET MARGIN
-5,118.8%
DEBT/EQUITY
7.79
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.1%
FLOAT SHARES
123,372,662
AVG. DAILY VOLUME (30D)
1,329,591
Institutional holders
Comparable stocks
Frequently asked questions about Milestone Pharmaceuticals stock
What does Milestone Pharmaceuticals do?
Milestone Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Joseph G. Oliveto, the company employs around 38 people.
The IPO was on 09/05/2019; the stock trades on NASDAQ under the ticker MIST.
What do analysts say about Milestone Pharmaceuticals stock?
7 analysts rate the stock, the consensus is Buy (as of 03/09/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Milestone Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -28% stronger than usual.
Does Milestone Pharmaceuticals pay a dividend?
No, Milestone Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Milestone Pharmaceuticals?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Milestone Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Milestone Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.